PPARG and Hepatic steatosis: In summary, this study provided substantial experimental evidence that clopidogrel can prevent and reverse HFD-induced hepatic steatosis in mice through enhanced phosphorylation of the AMPK signaling pathway and suppression of PPARG-mediated uptake of fatty acids in the liver and primary hepatocytes of mice, suggesting that clopidogrel could be repurposed to fight MASLD for future patient care.